UniProtKB/Swiss-Prot P13747 : Variant p.Asn98Lys
HLA class I histocompatibility antigen, alpha chain E
Gene: HLA-E
Feedback ?
Variant information
Variant position:
98
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Asparagine (N) to Lysine (K) at position 98 (N98K, p.Asn98Lys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and polar (N) to large size and basic (K)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Polymorphism:
The following alleles are known: E*01:01 and E*01:03 (PubMed:10064069 , PubMed:16570139 , PubMed:16702430 , PubMed:28127896 , PubMed:3131426 ). The frequency of E*01:01 and E*01:03 alleles in the population is about equal suggesting balanced selection in diverse populations. Evolutionary studies suggest that E*01:03 is the original allele (PubMed:12445303 ). Two other alleles has been described E*01:02 and E*01:04 (PubMed:1977695 , PubMed:3260916 ). Allele E*01:02 was found to be identical to HLA E*01:01 (PubMed:22665232 , PubMed:3260916 ). The existence of allele E*01:04 is uncertain as it could not be confirmed in further studies (PubMed:12445303 , PubMed:1977695 ). The sequence shown is that of E*01:03 (PubMed:10064069 , PubMed:16570139 , PubMed:16702430 , PubMed:28127896 ).
Additional information on the polymorphism described.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
98
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
358
The length of the canonical sequence.
Location on the sequence:
SEYWDRETRSARDTAQIFRV
N LRTLRGYYNQSEAGSHTLQW
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human SEYWDRETRSARDTAQIFRVN LRTLRGYYNQSEAGSHTLQW
Chimpanzee SEYWDRETRSARDTAQIFRVN LRTLRGYYNQSEAGSHTLQW
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
22 – 358
HLA class I histocompatibility antigen, alpha chain E
Topological domain
22 – 305
Extracellular
Region
22 – 111
Alpha-1
Binding site
84 – 84
Binding site
87 – 87
Binding site
98 – 98
Binding site
98 – 98
Binding site
105 – 105
Binding site
105 – 105
Glycosylation
107 – 107
N-linked (GlcNAc...) asparagine
Mutagenesis
83 – 83
R -> A. Has no impact on the affinity for KLRD1-KLRC1.
Mutagenesis
86 – 86
R -> A. Reduces the affinity for KLRD1-KLRC1.
Mutagenesis
90 – 90
D -> A. Has no impact on the affinity for KLRD1-KLRC1.
Mutagenesis
93 – 93
Q -> A. Impairs the recognition by KLRD1-KLRC1.
Mutagenesis
96 – 96
R -> A. Abolishes the recognition by KLRD1-KLRC1.
Mutagenesis
97 – 97
V -> A. Impairs the recognition by KLRD1-KLRC1.
Mutagenesis
100 – 100
R -> A. Reduces the affinity for KLRD1-KLRC1.
Mutagenesis
110 – 110
E -> A. Has no impact on the affinity for KLRD1-KLRC1.
Helix
78 – 105
Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.